In addition to thyroid cancer, observational and pharmacovigilance studies have investigated potential associations between GLP-1 RA use and other malignancies—including pancreatic, colorectal, and breast cancers—with inconsistent results [13–15]. The gene discussed is GCG; the disease is breast cancer.